Evelo Biosciences' lead drug candidate has failed a midstage trial in atopic dermatitis, wreaking havoc with its share price, but the biotech says it still plans to go ahe
Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune disease
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatme
